Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE)

Rosario Martinez-Vega, Nicole L.De La Mata, Nagalingeswaran Kumarasamy, Penh Sun Ly, Kinh Van Nguyen, Tuti P. Merati, Thi Thanh Pham, Man Po Lee, Jun Yong Choi, Jeremy L. Ross, Oon Tek Ng

Research output: Contribution to journalArticle

Abstract

Background: The durability of first-line regimen is important to achieve long-term treatment success for the management of HIV infection. Our analysis describes the duration of sequential ART regimens and identifies the determinants leading to treatment change in HIV-positive patients initiating in Asia. Methods: All HIV-positive adult patients initiating first-line ART in 2003–2013, from eight clinical sites among seven countries in Asia. Patient follow-up was to May 2014. Kaplan–Meier curves were used to estimate the time to second-line ART and third-line ART regimen. Factors associated with treatment durability were assessed using Cox proportional hazards model. Results: A total of 16,962 patients initiated first-line ART. Of these, 4,336 patients initiated second-line ART over 38,798 person-years (pys), a crude rate of 11.2 (95% CI 10.8, 11.5) per 100 pys. The probability of being on first-line ART increased from 83.7% (95% CI 82.1, 85.1%) in 2003–2005 to 87.9% (95% CI 87.1, 88.6%) in 2010–2013. Third-line ART was initiated by 1,135 patients over 8,078 pys, a crude rate of 14.0 (95% CI 13.3, 14.9) per 100 pys. The probability of continuing second-line ART significantly increased from 64.9% (95% CI 58.5, 70.6%) in 2003–2005 to 86.2% (95% CI 84.7, 87.6%) in 2010–2013. Conclusions: Rates of discontinuation of first- and second-line regimens have decreased over the last decade in Asia. Subsequent regimens were of shorter duration compared to the first-line regimen initiated in the same year period. Lower CD4+ T-cell count and the use of suboptimal regimens were important factors associated with higher risk of treatment switch.

Original languageEnglish
Pages (from-to)167-178
Number of pages12
JournalAntiviral therapy
Volume23
Issue number2
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

HIV-1
HIV
Databases
Therapeutics
CD4 Lymphocyte Count
Proportional Hazards Models
HIV Infections
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Martinez-Vega, R., La Mata, N. L. D., Kumarasamy, N., Ly, P. S., Van Nguyen, K., Merati, T. P., ... Ng, O. T. (2018). Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE). Antiviral therapy, 23(2), 167-178. https://doi.org/10.3851/IMP3194
Martinez-Vega, Rosario ; La Mata, Nicole L.De ; Kumarasamy, Nagalingeswaran ; Ly, Penh Sun ; Van Nguyen, Kinh ; Merati, Tuti P. ; Pham, Thi Thanh ; Lee, Man Po ; Choi, Jun Yong ; Ross, Jeremy L. ; Ng, Oon Tek. / Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE). In: Antiviral therapy. 2018 ; Vol. 23, No. 2. pp. 167-178.
@article{dd03acf20b944037befb55ba0cb10724,
title = "Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE)",
abstract = "Background: The durability of first-line regimen is important to achieve long-term treatment success for the management of HIV infection. Our analysis describes the duration of sequential ART regimens and identifies the determinants leading to treatment change in HIV-positive patients initiating in Asia. Methods: All HIV-positive adult patients initiating first-line ART in 2003–2013, from eight clinical sites among seven countries in Asia. Patient follow-up was to May 2014. Kaplan–Meier curves were used to estimate the time to second-line ART and third-line ART regimen. Factors associated with treatment durability were assessed using Cox proportional hazards model. Results: A total of 16,962 patients initiated first-line ART. Of these, 4,336 patients initiated second-line ART over 38,798 person-years (pys), a crude rate of 11.2 (95{\%} CI 10.8, 11.5) per 100 pys. The probability of being on first-line ART increased from 83.7{\%} (95{\%} CI 82.1, 85.1{\%}) in 2003–2005 to 87.9{\%} (95{\%} CI 87.1, 88.6{\%}) in 2010–2013. Third-line ART was initiated by 1,135 patients over 8,078 pys, a crude rate of 14.0 (95{\%} CI 13.3, 14.9) per 100 pys. The probability of continuing second-line ART significantly increased from 64.9{\%} (95{\%} CI 58.5, 70.6{\%}) in 2003–2005 to 86.2{\%} (95{\%} CI 84.7, 87.6{\%}) in 2010–2013. Conclusions: Rates of discontinuation of first- and second-line regimens have decreased over the last decade in Asia. Subsequent regimens were of shorter duration compared to the first-line regimen initiated in the same year period. Lower CD4+ T-cell count and the use of suboptimal regimens were important factors associated with higher risk of treatment switch.",
author = "Rosario Martinez-Vega and {La Mata}, {Nicole L.De} and Nagalingeswaran Kumarasamy and Ly, {Penh Sun} and {Van Nguyen}, Kinh and Merati, {Tuti P.} and Pham, {Thi Thanh} and Lee, {Man Po} and Choi, {Jun Yong} and Ross, {Jeremy L.} and Ng, {Oon Tek}",
year = "2018",
month = "1",
day = "1",
doi = "10.3851/IMP3194",
language = "English",
volume = "23",
pages = "167--178",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "2",

}

Martinez-Vega, R, La Mata, NLD, Kumarasamy, N, Ly, PS, Van Nguyen, K, Merati, TP, Pham, TT, Lee, MP, Choi, JY, Ross, JL & Ng, OT 2018, 'Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE)', Antiviral therapy, vol. 23, no. 2, pp. 167-178. https://doi.org/10.3851/IMP3194

Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE). / Martinez-Vega, Rosario; La Mata, Nicole L.De; Kumarasamy, Nagalingeswaran; Ly, Penh Sun; Van Nguyen, Kinh; Merati, Tuti P.; Pham, Thi Thanh; Lee, Man Po; Choi, Jun Yong; Ross, Jeremy L.; Ng, Oon Tek.

In: Antiviral therapy, Vol. 23, No. 2, 01.01.2018, p. 167-178.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE)

AU - Martinez-Vega, Rosario

AU - La Mata, Nicole L.De

AU - Kumarasamy, Nagalingeswaran

AU - Ly, Penh Sun

AU - Van Nguyen, Kinh

AU - Merati, Tuti P.

AU - Pham, Thi Thanh

AU - Lee, Man Po

AU - Choi, Jun Yong

AU - Ross, Jeremy L.

AU - Ng, Oon Tek

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The durability of first-line regimen is important to achieve long-term treatment success for the management of HIV infection. Our analysis describes the duration of sequential ART regimens and identifies the determinants leading to treatment change in HIV-positive patients initiating in Asia. Methods: All HIV-positive adult patients initiating first-line ART in 2003–2013, from eight clinical sites among seven countries in Asia. Patient follow-up was to May 2014. Kaplan–Meier curves were used to estimate the time to second-line ART and third-line ART regimen. Factors associated with treatment durability were assessed using Cox proportional hazards model. Results: A total of 16,962 patients initiated first-line ART. Of these, 4,336 patients initiated second-line ART over 38,798 person-years (pys), a crude rate of 11.2 (95% CI 10.8, 11.5) per 100 pys. The probability of being on first-line ART increased from 83.7% (95% CI 82.1, 85.1%) in 2003–2005 to 87.9% (95% CI 87.1, 88.6%) in 2010–2013. Third-line ART was initiated by 1,135 patients over 8,078 pys, a crude rate of 14.0 (95% CI 13.3, 14.9) per 100 pys. The probability of continuing second-line ART significantly increased from 64.9% (95% CI 58.5, 70.6%) in 2003–2005 to 86.2% (95% CI 84.7, 87.6%) in 2010–2013. Conclusions: Rates of discontinuation of first- and second-line regimens have decreased over the last decade in Asia. Subsequent regimens were of shorter duration compared to the first-line regimen initiated in the same year period. Lower CD4+ T-cell count and the use of suboptimal regimens were important factors associated with higher risk of treatment switch.

AB - Background: The durability of first-line regimen is important to achieve long-term treatment success for the management of HIV infection. Our analysis describes the duration of sequential ART regimens and identifies the determinants leading to treatment change in HIV-positive patients initiating in Asia. Methods: All HIV-positive adult patients initiating first-line ART in 2003–2013, from eight clinical sites among seven countries in Asia. Patient follow-up was to May 2014. Kaplan–Meier curves were used to estimate the time to second-line ART and third-line ART regimen. Factors associated with treatment durability were assessed using Cox proportional hazards model. Results: A total of 16,962 patients initiated first-line ART. Of these, 4,336 patients initiated second-line ART over 38,798 person-years (pys), a crude rate of 11.2 (95% CI 10.8, 11.5) per 100 pys. The probability of being on first-line ART increased from 83.7% (95% CI 82.1, 85.1%) in 2003–2005 to 87.9% (95% CI 87.1, 88.6%) in 2010–2013. Third-line ART was initiated by 1,135 patients over 8,078 pys, a crude rate of 14.0 (95% CI 13.3, 14.9) per 100 pys. The probability of continuing second-line ART significantly increased from 64.9% (95% CI 58.5, 70.6%) in 2003–2005 to 86.2% (95% CI 84.7, 87.6%) in 2010–2013. Conclusions: Rates of discontinuation of first- and second-line regimens have decreased over the last decade in Asia. Subsequent regimens were of shorter duration compared to the first-line regimen initiated in the same year period. Lower CD4+ T-cell count and the use of suboptimal regimens were important factors associated with higher risk of treatment switch.

UR - http://www.scopus.com/inward/record.url?scp=85047163687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047163687&partnerID=8YFLogxK

U2 - 10.3851/IMP3194

DO - 10.3851/IMP3194

M3 - Article

C2 - 28933705

AN - SCOPUS:85047163687

VL - 23

SP - 167

EP - 178

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 2

ER -